Laboratório da Interação Parasita-Hospedeiro e Epidemiologia (LAIPHE) Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Curso de Medicina, Centro Universitário Christus, Fortaleza, Brazil.
Front Immunol. 2021 Jun 24;12:647987. doi: 10.3389/fimmu.2021.647987. eCollection 2021.
Cutaneous leishmaniasis caused by induces a pronounced Th1 inflammatory response characterized by IFN-γ production. Even in the absence of parasites, lesions result from a severe inflammatory response in which inflammatory cytokines play an important role. Different approaches have been used to evaluate the therapeutic potential of orally administrated heat shock proteins (Hsp). These proteins are evolutionarily preserved from bacteria to humans, highly expressed under inflammatory conditions and described as immunodominant antigens. Tolerance induced by the oral administration of Hsp65 is capable of suppressing inflammation and inducing differentiation in regulatory cells, and has been successfully demonstrated in several experimental models of autoimmune and inflammatory diseases. We initially administered recombinant () prior to infection as a proof of concept, in order to verify its immunomodulatory potential in the inflammatory response arising from . Using this experimental approach, we demonstrated that the oral administration of a recombinant strain, which produces and secretes Hsp65 from directly into the gut, mitigated the effects of inflammation caused by infection in association or not with PAM 3CSK4 (-α-Palmitoyl--[2,3-bis(palmitoyloxy)-(2)-propyl]-L-cysteine, a TLR2 agonist). This was evidenced by the production of anti-inflammatory cytokines and the expansion of regulatory T cells in the draining lymph nodes of BALB/c mice. Our experimental results suggest that IL-10, TLR-2 and LAP are important immunomodulators in infection. In addition, recombinant administered 4 weeks after infection was observed to decrease lesion size, as well as the number of parasites, and produced a higher IL-10 production and decrease IFN-γ secretion. Together, these results indicate that Hsp65-producing can be considered as an alternative candidate for treatment in both autoimmune diseases, as well as in chronic infections that cause inflammatory disease.
皮肤利什曼病由 引起,导致强烈的 Th1 炎症反应,其特征是 IFN-γ 的产生。即使没有寄生虫,病变也是由严重的炎症反应引起的,其中炎症细胞因子起着重要作用。已经使用了不同的方法来评估口服热休克蛋白 (Hsp) 的治疗潜力。这些蛋白质在从细菌到人类的进化过程中都得到了保存,在炎症条件下高度表达,并被描述为免疫优势抗原。口服 Hsp65 诱导的耐受能够抑制炎症并诱导调节性细胞分化,并已在几种自身免疫和炎症性疾病的实验模型中得到成功验证。我们最初在感染前给予重组 (),作为一个概念验证,以验证其在 引起的炎症反应中的免疫调节潜力。使用这种实验方法,我们证明了口服重组 株(该株能够直接从肠道分泌和分泌 Hsp65)减轻了 感染引起的炎症的影响,无论是否与 TLR2 激动剂 PAM 3CSK4(-α-棕榈酰--[2,3-二(棕榈酰氧基)-(2)-丙基]-L-半胱氨酸)一起使用。这是通过在 BALB/c 小鼠的引流淋巴结中产生抗炎细胞因子和扩增调节性 T 细胞来证明的。我们的实验结果表明,IL-10、TLR-2 和 LAP 是 感染中的重要免疫调节剂。此外,在感染后 4 周给予重组 观察到病变面积减小,寄生虫数量减少,同时产生更高的 IL-10 产生和减少 IFN-γ 分泌。总之,这些结果表明,产 Hsp65 的 可被视为治疗自身免疫性疾病以及引起炎症性疾病的慢性感染的一种替代候选物。